18F-FDG, Immunotherapy, Melanoma, NSCLC, Positron-Emission Tomography
Conditions
Keywords
melanoma, NSCLC, FDG, PET, immunotherapy
Brief summary
Study the EFS and OS according to 18FDG PET in patients with melanoma or non small cell lung cancer treated by immunotherapy.
Detailed description
Study EFS in patients with melanoma or NSCLC treated by immunotherapy (anti CTLA4 or anti PDL1) and performed18FDG PET Multicentric retrospective study
Interventions
None listed
Sponsors
University Hospital, Brest
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* patients treated for melanoma or NSCLC with immunotherapy (anti CTLA4 or antiPDL1) * patients treated in Brest, Morlaix, Landerneau hospital * patients performed FDG PET * no opposition to study
Exclusion criteria
* age under 18 years old * refusal to participate
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| measure of progression free survival (obtained by the delay between the date of initiation of immunotherapy until the date of first documented progression disease in patients with melanoma or NSCLC treated by immunotherapy | up to 50 months | From date of initiation of treatment until the date of first documented progression disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| measure of overall survival (obtained by the delay between the date of initiation of immunotherapy until the date of death related to disease in patients with melanoma or NSCLC treated by immunotherapy | up to 50 months | From date of initiation of treatment until the date of death related to disease according to different criteria in interim PET/CT 1. 18F-FDG PET/CT imaging was performed prior to (18F-FDG PET/CT 0) and 14 weeks after ICI onset (18F-FDG PET/CT 1). Assessment of patient response to treatment was done according to RECIST1.1, iRECIST, PERCIST and PECRIT criteria. |
| Study different criteria (RECIST, iRECIST, PERCIST and PECRIT) to predict PFS or OS | up to 50 months | Interpretation according to 4 criteria to predict response to immunotherapy |
| study the potential correlation between PET data and clinicobiological data | up to 50 months | correlation between adverse events (AE) due to immunotherapy described on PET data and AE detected on clinicobiological data |
Countries
France
Outcome results
None listed